Table 3.

General information and therapeutic outcomes on 5 patients with coexistent genetic alterations including EGFR, ROS1, and EML4-ALK in MPA and LA patients

Patients	1	2	3	4	5
Gender	Female	Male	Female	Male	Female
Age (years)	52	31	45	71	75
Smoking history	Never	Never	Never	Ever	Never
Lymphovascular invasion	Absent	Present	Absent	Absent	Absent
Tumor differentiation	Moderate	Moderate	Moderate	Moderate	Moderate
Stage	T1bN0M0	T1cN1M0	T1cN0M0	T1bN0M0	T1cN0M0
Pathological type	MPA	MPA	MPA	MPA	LA
Mutation status	ROS1+; EML4-ALK+	ROS1+; EML4-ALK+	EGFR L858R+; ROS1+	EGFR L858R+; ROS1+	EGFR 19-del+; ROS1+
Therapeutic intervention	Surgery; chemotherapy; crizotinib	Surgery; chemotherapy; crizotinib	Surgery; chemotherapy; EGFR inhibitors	Surgery; chemotherapy; EGFR inhibitors	Surgery; chemotherapy; EGFR inhibitors
Outcomes	Partial response	Partial response	Partial response	Recurrence	Partial response

MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component, EGFR+ EGFR mutation, ROS1+ ROS1 fusion, EML4-ALK+ EML4-ALK fusion